NSE · DCAL · Pharmaceuticals
Dishman Carbogen Amcis Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹69 Cr with net profit ₹-4 Cr — a -6.32% net margin, versus -58.29% the period before.
Shareholding
As of 2026-06-30
- Promoter59.32%
- Public31.75%
- FII6.86%
- DII2.07%
49,430 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.51× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #41 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 176.1 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 88.75 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 19.67 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Dishman Carbogen Amcis Ltd.(this company) | ₹2,947 Cr | 135.24 | 0.44 | 1.46% | 0.03% |
AI analysis
AI-generated · google/gemini-2.5-flashDishman Carbogen Amcis Ltd. (DCAL) is listed with a market capitalization of Rs 2992 Cr. The company reported revenue of Rs 2733.18 Cr and a net profit margin of 332.4%. Its P/E ratio stands at 137.29, with an EPS of Rs 6.32. The debt-to-equity ratio is 0.41.
Positives
- +The company has a high net profit margin of 332.4%.
- +Return on equity (ROE) is significantly high at 146%.
- +The debt-to-equity ratio is moderate at 0.41.
Negatives
- −The P/E ratio is high at 137.29, which may suggest a premium valuation.
- −The Return on Capital Employed (ROCE) is relatively low at 2.6619% compared to its ROE.
- −Net profit in Dec 2025 was negative at Rs -12.97 Cr despite a revenue of Rs 719.8 Cr.
- −Quarterly net profit for Sept 2025 saw a decline to Rs 65.27 Cr from Rs 23.41 Cr in Jun 2025, while Dec 2025 saw a net loss.
Financial Performance
Dishman Carbogen Amcis Ltd. recorded revenue of Rs 2733.18 Cr, with an annual revenue growth of 3.7%. The net profit for the period Mar 2025 was Rs 3.24 Cr. Quarterly revenue for Mar 2026 was Rs 851.4 Cr, with a net profit of Rs 21.74 Cr. This follows a net profit of Rs -12.97 Cr in Dec 2025 on revenue of Rs 719.8 Cr.
Profitability & Returns
The company's net profit margin is 332.4%. Return on equity (ROE) is 146%, while return on capital employed (ROCE) stands at 2.6619%. Earnings per share (EPS) for Mar 2025 was Rs 0.21. In Mar 2026, the company reported a net profit of Rs 21.74 Cr on revenue of Rs 851.4 Cr.
Balance Sheet
Dishman Carbogen Amcis Ltd. has a book value per share of Rs 425.87. The debt-to-equity ratio is 0.41, indicating a moderate level of leverage. No information on current assets or liabilities is available in the provided data.
Ownership & Pledges
Public shareholding accounts for 31.5964%. There are no promoter shares pledged, with promoter pledge at 0%.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Dishman Carbogen Amcis Ltd.share price & fundamentals